#USA #Cambridge #Nona Biosciences #Harbour Mice #Atossa Therapeutics

Nona Biosciences and Atossa Therapeutics Collaborate on Antibody Therapies

In an exciting advancement in the battle against breast cancer, Nona Biosciences has announced a research collaboration with Atossa Therapeutics. This partnership aims to discover next-generation antibody therapies that could significantly improve treatment options for patients. Nona Biosciences, recognized for its robust biotechnology innovations, extends its expertise in integrated solutions from the concept phase to Investigational New Drug (IND) approval.

The collaboration will utilize Nona's proprietary H2L2 Harbour Mice® platform, a unique technology that employs transgenic mice to create fully human monoclonal antibodies. These antibodies are generated in two formats: the classical two heavy and two light chain (H2L2) as well as the heavy chain-only (HCAb) format. This innovative approach eliminates the necessity for extensive engineering or humanization processes, simplifying the pathway to effective treatments.

Partnering with Atossa Therapeutics, known for their focus on innovative oncology solutions, allows Nona to leverage its Harbour Mice® platform effectively. The partnership aims to secure rapid identification of promising therapeutic candidates tailored for breast cancer. Dr. Jingsong Wang, Chairman of Nona Biosciences, expressed enthusiasm about this collaboration, affirming that it aligns perfectly with their mission to create cutting-edge antibody therapies. He stated, "This partnership highlights the value of our proprietary Harbour Mice® platform and reflects the industry's growing demand for innovative antibody discovery solutions."

The Harbour Mice® platform has already proven its efficacy, having been utilized in over 250 drug discovery programs across various therapeutic areas. This extensive application showcases the platform's versatility and reliability in creating effective monoclonal antibodies that are ready for clinical exploration.

Nona Biosciences distinguishes itself by offering a comprehensive solution in the field of antibody discovery. Their process is streamlined and includes crucial steps such as antigen preparation, animal immunization, single B cell screening, antibody lead generation, and rigorous pharmacological evaluation. By integrating these processes, Nona positions itself as a leader in therapeutic antibody development, specifically targeting significant diseases such as cancer.

The collaboration with Atossa Therapeutics represents a promising step forward in oncology research, especially in developing antibodies that can address the pressing medical needs of breast cancer patients. The partnerships formed between biotech companies often lead to groundbreaking discoveries, and this one could yield transformative therapies that change the course of treatment options available in oncology.

As Nona Biosciences continues to push the boundaries with its advanced technologies, the collaboration with Atossa serves as a reminder of the potential for biotechnology to create innovative solutions where they are most needed. Together, they are working towards a future where breast cancer treatments are more effective and accessible, demonstrating the power of collaboration in the mission to save lives.

For more information on Nona Biosciences and their innovative platforms, visit Nona Biosciences.